| 1. |
刘会, 梁田, 刘桐希, 等. 抗合成酶综合征合并肺间质疾病的临床及影像征象分析. 中华放射学杂志, 2017, 51(10): 750-755.
|
| 2. |
Fu H, Zheng Z, Zhang Z, et al. Prediction of progressive pulmonary fibrosis in patients with anti-synthetase syndrome-associated interstitial lung disease. Clin Rheumatol, 2023, 42(7): 1917-1929.
|
| 3. |
Bell PT, Beaton T, Terrill M, et al. Anti-synthetase syndrome associated interstitial lung disease after combination dual immune checkpoint inhibition. Respirol Case Rep, 2023, 11(4): e01115.
|
| 4. |
Marguerie C, Bunn CC, Beynon HL, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med, 1990, 77(282): 1019-1038.
|
| 5. |
Lilleker JB, Vencovsky J, Wang G, et al. The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis, 2018, 77(1): 30-39.
|
| 6. |
Costa AN, Kawano-Dourado L, Shinjo SK, et al. Environmental exposure in inflammatory myositis. Clin Rheumatol, 2014, 33(11): 1689-1690.
|
| 7. |
Opinc AH, Makowska JS. Antisynthetase syndrome - much more than just a myopathy. Semin Arthritis Rheum, 2021, 51(1): 72-83.
|
| 8. |
罗澜, 邢晓燕, 肖云抒, 等. 抗合成酶综合征合并心脏受累患者的临床及免疫学特征. 北京大学学报(医学版), 2021, 53(6): 1078-1082.
|
| 9. |
Gasparotto M, Gatto M, Saccon F, et al. Pulmonary involvement in antisynthetase syndrome. Curr Opin Rheumatol, 2019, 31(6): 603-610.
|
| 10. |
Marco J L, Collins B F. Clinical manifestations and treatment of antisynthetase syndrome. Best Pract Res Clin Rheumatol, 2020, 34(4): 101503.
|
| 11. |
Shi J, Li S, Yang H, et al. Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies. J Rheumatol, 2017, 44(7): 1051-1057.
|
| 12. |
李文, 李俊, 谢万木, 等. 抗合成酶综合征合并间质性肺病患者的临床特征. 中华医学杂志, 2020, 100(24): 1861-1865.
|
| 13. |
赵娜, 刘颖, 孙小凤, 等. 不同抗氨酰tRNA合成酶抗体阳性的抗合成酶综合征60例临床和影像学相关特征分析. 中华风湿病学杂志, 2019, 23(5): 320-325.
|
| 14. |
Zhan X, Yan W, Wang Y, et al. Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China. BMC Pulm Med, 2021, 21(1): 57.
|
| 15. |
Wilfong EM, Young-Glazer JJ, Sohn BK, et al. Anti-tRNA synthetase syndrome interstitial lung disease: a single center experience. Respir Med, 2022, 191: 106432.
|
| 16. |
赵琪, 邹如意, 田亚琼, 等. 糖皮质激素和他克莫司治疗抗合成酶综合征相关间质性肺疾病的疗效及安全性分析. 中国呼吸与危重监护杂志, 2023, 22(3): 176-181.
|
| 17. |
Xu L, Wang F, Luo F. Rituximab for the treatment of connective tissue disease-associated interstitial lung disease: a systematic review and meta-analysis. Front Pharmacol, 2022, 13: 1019915.
|
| 18. |
毛萌萌, 郭炳鹏, 韩茜. 利妥昔单抗在抗合成酶综合征相关性间质性肺炎中的治疗进展. 中华结核和呼吸杂志, 2019, 42(10): 776-779.
|
| 19. |
Mecoli CA, Christopher-Stine L. Management of interstitial lung disease in patients with myositis specific autoantibodies. Curr Rheumatol Rep, 2018, 20(5): 27.
|
| 20. |
Wu W, Collins BF, Gardner GC, et al. Antisynthetase syndrome-related interstitial lung disease (ASyS-ILD): longitudinal imaging findings. Eur Radiol, 2023, 33(7): 4746-4757.
|
| 21. |
Liu H, Xie S, Liang T, et al. Prognostic factors of interstitial lung disease progression at sequential HRCT in anti-synthetase syndrome. Eur Radiol, 2019, 29(10): 5349-5357.
|
| 22. |
Zhao N, Jiang W, Wu H, et al. Clinical features, prognostic factors, and survival of patients with antisynthetase syndrome and interstitial lung disease. Front Immunol, 2022, 13: 872615.
|
1/5
WeChat